Antitrust Antitrust

AstraZeneca allowed to withdraw suit after China's top court sidesteps in-depth review of pay-for-delay agreement

By MLex Staff
  • 26 Jan 2022 02:27
  • 26 Jan 2022 02:27
China's Supreme People's Court has permitted British-Swedish pharma company AstraZeneca, or AZ, to withdraw a lawsuit from the top court, after judges refrained from concluding that a pay-for-delay patent agreement at the center of the dispute violates the country's antitrust law.

AstraZeneca initially appealed to the top court a decision by the Nanjing

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments

TAKE A FREE TRIAL

Latest News